ViewRay Growth, Revenue, Number of Employees and Funding

Overview

Location:
Oakwood Village, OH USA
Total Funding:$301.4M
Industry:Medical Equip
Founded:2004
Lead Investor(s):Morgan Stanley, Jefferies
Press

Industry Ranking

State Ranking

Growjo 10k Ranking

Revenue & Financials

  • ViewRay's revenue is currently $167M per year.
  • ViewRay received $172.5M in venture funding in August 2018.
  • ViewRay's revenue per employee is $742222
  • ViewRay's total funding is $301.4M.

Employee Data

  • ViewRay has 225 Employees.
  • ViewRay grew their employee count by 36% last year.
  • ViewRay currently has 45 job openings.

What Is ViewRay?

MRI-GUIDED ADAPTIVE RADIOTHERAPY ViewRay®, Inc. (NASDAQ:VRAY), designs, manufactures, and markets the MRIdian® radiation therapy system to address the key limitations of existing external-beam radiation therapy technologies. MRIdian employs MRI-based technology to provide real-time imaging that clearly defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment. MRIdian allows physicians to record the level of radiation exposure that the tumor has received and adapt the prescription as needed. ViewRay believes this combination of enhanced visualization, on-line adapting and accurate dose recording will significantly improve the safety and efficacy of radiation therapy, leading to better outcomes for patients. At ViewRay, our vision is clear. We're dedicated to giving doctors new and better ways to treat cancer with radiation therapy. We're an entrepreneurial company with big ambitions, unlimited potential and a passion for improving the lives of patients with cancer. We're always on the lookout for talented people who share our commitment and values. Contact us if you're enthusiastic about working with a close-knit team and motivated by the prospect of making a difference.

keywords:Biotechnology,Healthcare,Medical Devices,Pharmaceuticals

225

Number of Employees

$167M

Revenue (est)

45

Current Jobs

36%

Employee Growth %

$301.4M

Total Funding

N/A

Valuation

N/A

Accelerator

B2B

Type

Similar Companies

NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
WillowWood
$23.8M1038%
Rock Medical Or...
$5.6M3119%
Bound Tree Medi...
$44.4M1865%
ForTec Medical
$59.2M2506%
Norman Noble
$44.2M1876%
Bound Tree Medi...
$44.4M1865%
Mobile Instrume...
$54.2M2296%
ForTec Medical
$59.2M2506%
Alpha Imaging
$27.6M12110%
Norman Noble
$44.2M1876%

ViewRay News

20-Mar-19 - Analysts Turn Mixed On ViewRay, Inc. (VRAY), Karyopharm

The shares of ViewRay, Inc. (NASDAQ:VRAY) has been pegged with a rating of Buy by B. Riley FBR in its latest research note that was

20-Mar-19 - Why ViewRay, Inc. (VRAY) Stock Rose, Up To 3.82%, in Trade Today

ViewRay, Inc. (NASDAQ:VRAY) is among the top gainers of the stock market today, skyrocketing 3.82% or (0.31 points) to $8.48 from its

20-Mar-19 - Intra-Day Analysts Focus on ViewRay, Inc. (VRAY), Kopin Corporation

ViewRay, Inc. (NASDAQ: VRAY) experienced a high price of $8.8 with a low value of $7.8 at the end of the last trading session, which followed

ViewRay Funding

DateAmountRoundLead InvestorsReference
2008-01-21$25.0MUndisclosedArticle
2009-04-14$25.0MBOrbiMed Advisors, Fidelity BiosciencesArticle
2012-03-14$45.0MCArticle
2013-05-22$15.0MUndisclosedArticle
2013-12-05$15.0MUndisclosedArticle
2013-12-18$30.0MUndisclosedCowealth Medical Holding Co LtdArticle
2015-01-13$16.3MUndisclosedArticle
2015-07-01$50.0MUndisclosedCRGArticle
2015-07-27$26.7MUndisclosedMultipleArticle
2015-08-20$29.4MUndisclosedArticle
2015-09-01$2.7MUndisclosedArticle
2016-08-22$13.8MUndisclosedOrbiMed Advisors, LLCArticle
2017-01-19$UndisclosedUndisclosedPuissance Capital ManagementArticle
2017-10-26$50.0MUndisclosedArticle
2018-02-27$59.0MUndisclosedArticle
2018-08-15$143.1MUndisclosedMorgan StanleyArticle
2018-08-20$172.5MUndisclosedMorgan StanleyArticle

ViewRay Executive Hires

DateNameTitleReference
2012-03-21Michael BrandtSVP SalesArticle
2013-02-05Chris A. RaanesPresident/CEOArticle
2016-06-10Ajay BansalChief Financial OfficerArticle
2018-07-25Scott DrakePresident/CEOArticle
2018-10-03James AlecxihChief Commercial OfficerArticle
2018-11-22Rob FuchsChief Human Resources OfficerArticle